RSPO3 and metabolic dysfunction-associated steatotic liver disease: snRNA-seq analysis revealed a marked and progressive downregulation of RSPO3 mRNA in HSCs with advancing stages fibrosis in patients with MASLD, alcohol-associated cirrhosis or alcoholic hepatitis (Fig. 5i), whereas RSPO3 levels were low and remained largely unchanged during disease progression in ECs from the same patients (Extended Data Fig. 11i).